Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: An international collaborative study

Blood

Volumn 118, Issue 6, 2011, Pages 1675-1684

  Moratto, Daniele ^a   Giliani, Silvia ^a   Bonfim, Carmem ^b   Mazzolari, Evelina ^c   Fischer, Alain ^d,e   Ochs, Hans D ^f   Cant, Andrew J ^g   Thrasher, Adrian J ^h   Cowan, Morton J ⁱ   Albert, Michael H ^j   Small, Trudy ^k   Pai, Sung Yun ^l   Haddad, Elie ^m   Lisa, Antonella ⁿ   Hambleton, Sophie ^g   Slatter, Mary ^g   Cavazzana Calvo, Marina ^d,e   Mahlaoui, Nizar ^e   Picard, Capucine ^d,e   Torgerson, Troy R ^f   Burroughs, Lauri ^f   Koliski, Adriana ^b   Neto, Jose Zanis ^b   Porta, Fulvio ^c   Qasim, Waseem ^h   Veys, Paul ^o   Kavanau, Kristina ⁱ   Hönig, Manfred ^p   Schulz, Ansgar ^p   Friedrich, Wilhelm ^p   Notarangelo, Luigi D ^q   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c SPEDALI CIVILI   (Italy)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Infectious Diseases Allergy   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m UNIVERSITY OF MONTREAL   (Canada)

ⁿ CNR   (Italy)

^o GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^p UNIVERSITY OF ULM   (Germany)

^q HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE ASSOCIATION; ENGRAFTMENT; EPIDEMIC MENINGITIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LINEAGE SPECIFIC CHIMERISM; LYMPHOCYTE COUNT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; TESTIS CARCINOMA; WISKOTT ALDRICH SYNDROME;

EID: 80051641437     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-319376     Document Type: Article

References (35)

1. Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009;15(1 suppl):84-90.
2. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117(4):725-738; quiz 739.
3. Bouma G, Burns SO, Thrasher AJ. Wiskott- Aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology. 2009;214(9):778-790.
4. Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113(25):6288-6295.
5. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78(4):635-644. Erratum in: Cell. 1994;79(5):922. (Pubitemid 24268586)
6. Thrasher AJ. New insights into the biology of Wiskott-Aldrich syndrome (WAS). Hematology Am Soc Hematol Educ Program. 2009:132-138.
7. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90(7):2680-2689. (Pubitemid 27413478)
8. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a singlecenter cohort of 55 patients. Pediatrics. 2003;111(5):e622-e627.
9. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456-464. (Pubitemid 38140073)
10. Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol. 2003;15(4):446-453. (Pubitemid 36774257)
11. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6):876-885. (Pubitemid 24379120)
12. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115(16):3231-3238.
13. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104(13):4010-4019. (Pubitemid 39620151)
14. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439-445.
15. Pai SY, Notarangelo LD. Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment. Immunol Allergy Clin North Am. 2010;30(2):179-194.
16. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97(6):1598-1603. (Pubitemid 32217223)
17. Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol. 2006;135(3):362-366. (Pubitemid 44484844)
18. Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 2006;38(10):671-679. (Pubitemid 44669682)
19. Friedrich W, Schütz C, Schulz A, Benninghoff U, Honig M. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res. 2009;44(1):18-24.
20. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and longterm survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-610.
21. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
22. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graftversus-host disease: a multicenter study. Blood. 2003;102(3):802-809. (Pubitemid 36917767)
23. Yamada M, Ohtsu M, Kobayashi I, et al. Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers. Blood. 1999;93(2):756-757. (Pubitemid 29035759)
24. Gennery AR, Cant AJ. The immunocompromised host: the patient with recurrent infection. Adv Exp Med Biol. 2004;549:109-117. (Pubitemid 38968187)
25. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002;100(13):4344-4350. (Pubitemid 35429672)
26. Liston A, Enders A, Siggs OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008;8(7):545-558. (Pubitemid 351913676)
27. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood. 2009;113(17):4114-4124.
28. Borghans JA, Bredius RG, Hazenberg MD, et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood. 2006;108(2):763-769. (Pubitemid 44061382)
29. Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cellimmunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood. 2007;109(10):4575-4581. (Pubitemid 46743429)
30. Mazzolari E, Forino C, Guerci S, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol. 2007;120(4):892-899. (Pubitemid 47542283)
31. Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood. 2009;114(7):1445-1453.
32. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood. 2008;112(10):4139-4147.
33. Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, et al. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood. 2008;112(10):4158-4169.
34. De Saint-Basile G, Schlegel N, Caniglia M, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome: similar regional assignment but distinct X-inactivation pattern in carriers. Ann Hematol. 1991;63(2):107-110.
35. de Saint Basile G, Fischer A. X-linked immunodeficiencies: clues to genes involved in T- and B-cell differentiation. Immunol Today. 1991;12(12):456-461.